Published in Clin Cancer Res on January 01, 2005
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One (2009) 1.72
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol (2006) 1.31
Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res (2013) 1.13
Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS One (2012) 1.07
Role of DMP1 and its future in lung cancer diagnostics. Expert Rev Mol Diagn (2008) 0.91
Prognostic markers in lung cancer: is it ready for prime time? Transl Lung Cancer Res (2014) 0.90
Ataxia-telangiectasia group D complementing gene (ATDC) promotes lung cancer cell proliferation by activating NF-κB pathway. PLoS One (2013) 0.90
Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomark Med (2008) 0.86
Anchorage-independent growth of pocket protein-deficient murine fibroblasts requires bypass of G2 arrest and can be accomplished by expression of TBX2. Mol Cell Biol (2008) 0.83
Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients. Cancer Res Treat (2008) 0.82
Differential impact of tumor suppressor pathways on DNA damage response and therapy-induced transformation in a mouse primary cell model. PLoS One (2010) 0.81
ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression. PLoS One (2015) 0.75
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology (2005) 9.83
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
Computed tomography screening and lung cancer outcomes. JAMA (2007) 8.01
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology (2012) 6.92
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2007) 5.79
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
The 2004 World Health Organization classification of lung tumors. Semin Roentgenol (2005) 5.23
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med (2002) 5.10
Lung cancer screening with CT: Mayo Clinic experience. Radiology (2003) 4.72
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg (2012) 4.68
Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst (2002) 4.50
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
CT screening for lung cancer: five-year prospective experience. Radiology (2005) 4.33
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A (2007) 4.05
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med (2010) 3.91
Laser-capture microdissection. Nat Protoc (2006) 3.80
Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med (2007) 3.72
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Non-small-cell lung cancer. Lancet (2011) 3.45
Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. Radiology (2007) 3.44
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med (2012) 3.42
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest (2010) 3.13
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol (2012) 3.10
The landscape of recombination in African Americans. Nature (2011) 3.06
Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med (2008) 3.04
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2015) 2.95
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 2.85
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.64
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2012) 2.46
US lung cancer trends by histologic type. Cancer (2014) 2.46
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst (2013) 2.45
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
5-year lung cancer screening experience: growth curves of 18 lung cancers compared to histologic type, CT attenuation, stage, survival, and size. Chest (2009) 2.45
International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol (2012) 2.45
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med (2003) 2.35
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol (2003) 2.32
p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol (2011) 2.24
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
TP53 and liver carcinogenesis. Hum Mutat (2003) 2.23
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol (2013) 2.22
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst (2012) 2.21
Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol (2002) 2.21
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 2.20
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol (2010) 2.15
Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med (2002) 2.11
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res (2004) 2.08
Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol (2003) 2.08
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res (2007) 2.07
Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am J Respir Cell Mol Biol (2003) 2.05
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res (2011) 2.03
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Advances in chemotherapy of non-small cell lung cancer. Chest (2006) 2.00